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OBJECTIVES The study aimed to determine the risk of death or urgent transplant for patients who survived
an initial 6 months on the outpatient heart transplant waiting list when criteria emphasizing
reduced peak oxygen consumption are used for transplant candidate selection.
BACKGROUND Waiting time is a key criterion for heart donor allocation. A recent single-center investigation
described decreasing survival benefit from transplant for patients who survived an initial 6
months on the outpatient waiting list.
METHODS Kaplan-Meier survival analyses were performed for 80 patients from the Hospital of the
University of Pennsylvania (HUP) listed from July 1986 to January 1991, and 132 patients
from Columbia-Presbyterian Medical Center (CPMC) listed from September 1993 to
September 1995. Survival from the time of outpatient listing for the entire group (ALL) was
compared to subsequent survival from 6 months onward for those patients who survived the
initial 6 months after placement on the outpatient list (6M). Both urgent transplant and left
ventricular assist device implantation were considered equivalent to death; elective transplant
was censored.
RESULTS Survival for 6M was not significantly better than ALL at HUP (subsequent 12 months: 60 6
7 vs. 60 6 6% [mean 6 SD]; p 5 0.89) nor at CPMC (subsequent 12 months: 60 6 6 vs.
48 6 5%; p 5 0.35). Survival for 6M at both centers was substantially lower than survival
following transplant from the outpatient list in the United States in 1995.
CONCLUSIONS When high-risk patients are selected for nonurgent transplant listing, mortality remains high,
even among those who survive the initial six months after listing. Time accrued on the waiting
list remains an appropriate criterion for donor allocation. (J Am Coll Cardiol 1999;33:
1189–95) © 1999 by the American College of Cardiology
The success of cardiac transplantation as a treatment for
severe heart disease has resulted in a severe shortage of
available donor organs (1,2). Suggested solutions to this
problem have included methods of expanding the donor
pool (3–11), various surgical alternatives to transplant (12–
17), and more restrictive transplant candidate criteria (1,18).
Once a patient is identified as a transplant candidate he or
she is listed with the United Network for Organ Sharing
(UNOS). The present heart donor allocation scheme awards
points for waiting time, priority status (i.e., status 1 for left
ventricular assist device patients or hospitalized patients on
inotropic support in an intensive care unit, and status 2 for
all others), weight, blood type and geography. Thus, the
longer a patient remains on the waiting list, the more likely
he or she is to receive the next donor organ. As heart failure
is a progressive disease, the application of waiting time as a
key factor in the distribution of organs is logical. However,
a study by Stevenson et al. (19) implied that prioritizing on
the basis of accumulated waiting time might not be appro-
priate for less urgent (UNOS status 2) candidates. In that
study, outpatient transplant candidates who survived the
initial six months on the waiting list without receiving a
transplant experienced a survival rate in the subsequent year
that was only marginally worse than would have been
expected following cardiac transplantation. We reexamined
this question by comparing the survival of UNOS 2 listed
transplant candidates to the subsequent survival of those
patients who survived six months on the waiting list at two
transplant centers where strict criteria for acceptance of
candidates were used. We also investigated the incidence
and outcome of candidates who experienced substantial
clinical improvement during the initial six months and were
therefore deactivated from the waiting list.
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METHODS
Study population. Two hundred sixty-eight (268) ambu-
latory patients aged #70 were evaluated for transplant
candidacy at the Hospital of the University of Pennsylvania
(HUP) between July 1, 1986, and December 31, 1991. At
Columbia-Presbyterian Medical Center (CPMC), 199 am-
bulatory patients #70 were evaluated between July 1, 1993,
and July 1, 1995. Eighty (80) patients (69 men and 11
women), age 54 6 9 years (mean 6 SD) at HUP and 132
patients (103 men, 29 women) age 52 6 11 years at CPMC
were accepted for UNOS 2 transplant listing. Clinical
characteristics and survival statistics for both samples have
been described previously (20).
At both centers, patients accepted for transplant listing
had New York Heart Association (NYHA) class III or class
IV functional limitations and severely reduced left ventric-
ular systolic function. A reduced peak exercise oxygen
consumption (V˙O2) was used to guide the selection of potential
transplant candidates. Peak V˙O2 ,14 mlzkg
21zmin21 was
considered a strong indication for transplant (21). Patients with
higher peak V˙O2 measurements were accepted as transplant
candidates if the percent of predicted peak V˙O2 was less than
40% (22,23) or for malignant ventricular arrhythmias uncon-
trolled with drugs or an implantable cardioverter-defibrillator,
or unmanageable fluid overload requiring recurrent admissions
for heart failure. Peak V˙O2 was measured during maximal
treadmill exercise testing using a modified Naughton protocol
and a metabolic cart (Sensor-Medics, Anaheim, California).
Patient follow-up. Patients were followed prospectively in
the heart failure clinics at HUP and CPMC at ,3-month
intervals. Measurements of peak V˙O2 were repeated no later
than six months after initial listing, or earlier if medical
therapy was modified or subjective clinical improvement was
noted. Patients for whom placement on the waiting list was
based on a reduced peak V˙O2 were removed from the
waiting list if they experienced significant subjective im-
provement, which was confirmed by an increase in peak V˙O2
of $2 mlzkg21zmin21 with achievement of an absolute peak
V˙O2 of $15 mlzkg
21zmin21 on two consecutive studies
performed at least two weeks apart. The date of transplant,
left ventricular assist device (LVAD) implantation, or death
without transplant was recorded for each patient, as was the
UNOS priority status (1 or 2) at the time of transplant. For
patients who remained alive and untransplanted, follow-up
was discontinued on January 1, 1993, at HUP and on
March 1, 1998, at CPMC.
Statistical analysis. All data are represented as mean 6
SD. Comparisons of clinical variables between patients at
HUP and CPMC were made by independent sample t,
Wilcoxon rank-sum test, or the Fisher exact tests as appro-
priate. Disease progression resulting in critical clinical de-
terioration or death—defined as death without transplant,
status 1 transplant (i.e., receiving mechanical or inotropic
support prior to transplantation) or LVAD insertion—was
the outcome event for this study. Follow-up was complete
in all patients.
To investigate whether clinical characteristics present at
listing could discriminate between patients who developed
an outcome event (as defined above) during the following
six months and those who did not, the clinical characteris-
tics of these two groups were compared. Patients whose
outcome was censored at ,6 months (i.e., alive without a
transplant or status 2 at the time of transplant) were not
included in either group.
At each center, “survival” (i.e., freedom from an outcome
event) from the time of listing for the entire group (ALL)
was compared to subsequent survival from six months
onward for the subgroup of patients (6M) who survived the
initial six months after listing and were not removed from
the waiting list for being “too well for transplant,” using the
Kaplan-Meier method and the log-rank test. UNOS status
2 transplant was treated as a censored observation (i.e.,
removed from follow-up “alive” at the time of transplant).
The power to detect a clinically significant difference in
survival between ALL and 6M was calculated for the data
from each center. An overall “experimentwise” power to
detect a significant difference in either study was also
determined using the addition rule of probability: power
(HUP or CPMC) 5 power (HUP) 1 power (CPMC) 2
power (HUP and CPMC).
Power calculations were performed with PASS statistical
software, version 6.0 (Number Cruncher Statistical Sys-
tems, Kaysville, Utah). All other calculations were per-
formed with SAS statistical software, version 6.12 for
Macintosh (SAS Institute, Cary, North Carolina). Statisti-
cal significance was defined as p # 0.05, without adjustment
for multiple comparisons.
RESULTS
Patient characteristics. Clinical characteristics of the study
populations are shown in Table 1, and are consistent with
the typical characteristics of UNOS status 2 patient samples:
mainly men in their mid-50s with ischemic cardiomyopa-
thy, NYHA class III heart failure and severely reduced
Abbreviations and Acronyms
ALL 5 entire cohort at HUP (or CPMC)
ACE 5 angiotensin-converting enzyme
CHF 5 congestive heart failure
CPMC 5 Columbia-Presbyterian Medical Center
HUP 5 Hospital of the University of Pennsylvania
LVAD 5 left ventricular assist device
NYHA 5 New York Heart Association
Peak V˙O2 5 peak exercise oxygen consumption
UNOS 5 United Network for Organ Sharing
6M 5 patients who survived for 6 months on the
UNOS status 2 waiting list without
receiving UNOS status 1 transplant or
LVAD
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LVEF and peak V˙O2. In comparison to the HUP cohort,
the CPMC group had a larger proportion with nonischemic
etiology and higher LVEF, but was similar with respect to
age, gender, NYHA class, peak V˙O2, and the proportion of
patients receiving an angiotensin-converting enzyme (ACE)
inhibitor, digoxin and a diuretic.
There were no statistically significant differences in pa-
tient outcomes during the initial six months after placement
on the UNOS status 2 list between the HUP and CPMC
samples (Table 2). At six months, there were trends toward
more patients remaining alive and untransplanted (68% vs.
55%, p 5 0.107) and fewer patients dying or receiving a
UNOS 1 transplant or LVAD (22% vs. 32%, p 5 0.061) at
HUP versus CPMC.
Only 4% of patients at each center (three patients at HUP
and five patients at CPMC) were removed from the waiting
list because of clinical and objective improvement during the
initial six-month period. None of the delisted patients at
HUP experienced an outcome event during follow-up
periods of 491, 624 and 933 days. Two of the five delisted
patients at CPMC survived without an outcome event
during follow-up periods of 857 and 927 days. The remain-
ing three CPMC patients died suddenly after 214, 824 and
846 days of follow-up.
There were 51 six-month survivors at HUP and 68 at
CPMC. Outcomes for the 6M groups are shown in Table
3. Survival for the 6M group was not significantly different
from overall survival for either sample (Figs. 1 and 2). At
HUP, survival for 6M versus ALL was 76 6 6% versus
77 6 5% at 6 months, 60 6 7% versus 60 6 6% at 12
months, and 39 6 9% versus 33 6 7% at 24 months,
respectively (p 5 0.89). Corresponding survival rates at
CPMC were 75 6 6% versus 62 6 4% at 6 months, 60 6
8% versus 48 6 5% at 12 months, and 35 6 5% versus 32 6
7% at 24 months, respectively (6M vs. ALL, p 5 0.35).
If the 12% absolute improvement in survival (60% vs.
48%) at one year at CPMC is considered clinically mean-
ingful, our study had 60% power to have found this
difference to be statistically significant at the 0.05 level. The
power to detect the same improvement in survival in the
HUP dataset was only 45%, due to the smaller sample size.
However, because these two datasets are independent, the
power to have found this 12% difference in either sample
was 78% (0.6 1 0.45 2 (0.6)(0.45)).
Superimposed on each figure are survival data from the
UNOS Scientific Registry for all adult patients who were
Table 1. Clinical Characteristics of Patient Subgroups
HUP CPMC
Number: 80 132
Age (yrs) 54 6 9 52 6 11
Gender (% male) 86 78
Etiology (% ischemic)** 71 44
LVEF (%)* 18 6 7 21 6 9
Peak V˙O2 (ml/kg/min) 12.0 6 5.0 12.5 6 3.5
NYHA class 3.1 6 0.7 3.0 6 0.5
Medications
ACE inhibitor 92 84
Digoxin 92 91
Diuretics 92 91
*p 5 0.01, and **p # 0.001 for comparison of HUP and CPMC groups; for all other
comparisons p . 0.05.
Table 2. Patient Outcomes for the Initial 6 Months After
Placement on the UNOS Status 2 Waiting List
Outcome
HUP
(n 5 80)
CPMC
(n 5 132)
UNOS 1 transplant 11 (14%) 25 (19%)
LVAD 0 (0%) 1 (1%)
Dead w/o transplant 6 (8%) 19 (14%)
Pump failure 1 (1%) 11 (8%)
Sudden death 4 (5%) 8 (6%)
Noncardiac 1 (1%) 0 (0%)
UNOS 2 transplant 9 (11%) 14 (11%)
Alive w/o transplant 54 (68%) 73 (55%)
Delisted (too well) 3 (4%) 5 (4%)
6-month survivors 51 (64%) 68 (52%)
Table 3. Patient Outcomes for the 6-Month Survivors Over the
Entire Follow-up Period
Outcome
HUP
(n 5 51)
CPMC
(n 5 68)
UNOS 1 transplant 13 (25%) 23 (34%)
LVAD 0 (0%) 2 (3%)
Dead w/o transplant 7 (14%) 15 (23%)
UNOS 2 transplant 14 (27%) 16 (24%)
Alive w/o transplant 17 (33%) 12 (18%)
Figure 1. Survival for ALL vs. 6M groups at HUP and posttrans-
plant survival for all patients transplanted in the United States in
1995 from the UNOS Registry. (Note: For patients in the 6M
group, time 0 on the survival curve represents six months.)
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UNOS status 2 at the time of transplantation in 1995. The
88 6 1% and 86 6 1% actuarial survival rates at six and 12
months after UNOS status 2 transplant were significantly
better than the survival rates for 6M at both HUP and
CPMC (both p , 0.0001).
Clinical characteristics of 6-month survivors (including
patients who were delisted during the first 6 months) and
nonsurvivors are shown in Table 4. No statistically signifi-
cant differences were present for individual clinical charac-
teristics. Although there was a trend toward higher LVEFs
in survivors at HUP (18 6 6% vs. 15 6 6%, p 5 0.055), no
difference was present for the CPMC group (20 6 8
[survivors] vs. 21 6 10 [nonsurvivors], p 5 0.55).
DISCUSSION
The study suggests that when selection criteria emphasizing
reduced peak V˙O2 are used to select outpatient candidates
for cardiac transplantation, a high risk of death or urgent
transplantation is present well beyond the initial six months
after placement on the waiting list. The UNOS status 2
patients who survive the initial six months of transplant
listing without receiving a donor organ continue to experi-
ence a high risk of death or need for urgent transplant.
Because this risk remains well in excess of the risk of death
following cardiac transplantation, the present policy of
UNOS 2 listing prioritization, which awards credit for time
spent on the waiting list, continues to be appropriate.
Over the past decade there has been a consistent rise in
the referral of potential heart transplant candidates. This has
resulted in the growth of the transplant waiting list from
1,030 in 1988 to 3,698 in 1996 (2). During this same
period, the proportion of patients waiting more than one
year has increased from 12.5% to 50.6% (2). The supply of
donor organs has not kept pace—in fact, heart donation has
plateaued at approximately 2,500 annually for each of the
past four years (2). Various approaches to addressing this
supply-demand imbalance have been suggested: lowering
the age cutoff for transplant candidates (1), accepting hearts
from older donors (3–7), accepting donor hearts with
preexisting coronary artery disease for combined coronary
artery bypass grafting and transplant (8,9), cardiomyoplasty
(12–14), mitral valve repair alone (17), or with partial left
ventriculectomy (16), permanent LVAD implantation
(15,24) and xenotransplantation (10).
Another approach would involve changing the current
U.S. organ allocation system for outpatient candidates. At
present, excluding consideration of blood group and weight
range, outpatient prioritization is awarded solely on the
basis of waiting time. This is rational and equitable if the
mortality rate remains high among patients who have
remained on the waiting list without receiving a transplant.
Referral to a transplant center and subsequent placement on
the waiting list often follows a recent deterioration, so
mortality during the following few months is expected to be
high. However, careful medical management at a transplant
center might result in substantially improved survival.
Studying this question, Stevenson and colleagues at UCLA
observed a 67% one-year actuarial survival without trans-
plantation for 214 outpatients from the time of placement
on the waiting list. However, for outpatients who had
already survived 6 months from the time of listing, survival
without transplant was 83% over the subsequent year (19).
This was only slightly worse than the 88% one-year survival
following cardiac transplantation at their institution, and
Figure 2. Survival for ALL vs. six-month groups at CPMC and
posttransplant survival for all patients transplanted in the United
States in 1995 from the UNOS Registry. (Note: For patients in the
6M group, time 0 on the survival curve represents six months.)
Table 4. Clinical Characteristics for 6-Month Survivors versus Nonsurvivors at HUP and
CPMC*
HUP
Survivors
HUP
Nonsurvivors
CPMC
Survivors
CPMC
Nonsurvivors
Number of patients 54 17 75 45
Etiology (% ischemic) 71 67 43 51
NYHA class 3.3 6 0.5 3.0 6 0.8 3.0 6 0.6 3.1 6 0.5
LVEF (%) 18 6 6† 15 6 6 20 6 8 19 6 7
Peak V˙O2 (ml/kg/min) 12.2 6 4.7 10.6 6 6.1 12.6 6 3.5 12.3 6 3.8
*See text for details on how groups were defined for this analysis.
†p 5 0.055 for HUP Survivors vs. Nonsurvivors; all others p . 0.05.
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compares favorably to the 83% one-year survival after heart
transplantation in the United States (2).
A study by Kao et al. (25) seemed to confirm the UCLA
groups findings in that subsequent mortality among patients
who survived an initial six months on an outpatient waiting
list was only 6% at six months and 12% at 12 months.
However, when patients on inotropic support at the time of
transplantation were considered to have died (while still
awaiting transplant) three months after the date of their
transplant, the overall pretransplant mortality rate increased
to 13% at six months and 35% after 12 months.
Neither of the aforementioned studies used rigorous
selection criteria emphasizing reduced peak V˙O2. When
these criteria are applied this phenomena of altered short-
versus long-term survival may not persist. Congestive heart
failure (CHF) is a progressive disease. If patients are placed
on the waiting list only after medical therapy has been
optimized, the mortality rate on the waiting list should
continue to be substantial as the mean waiting time in-
creases. Moreover, clinical improvement of a sufficient
degree to allow candidate deactivation should be infrequent.
In our series it is not surprising that subsequent one-year
survival for six-month survivors at HUP and CPMC (60
and 62%, respectively) was similar to survival for each entire
cohort.
The survival time-censoring methodology used by
Stevenson and colleagues (19) may have given a false
impression of a good outcome for 6-month survivors in the
UCLA study. In both our studies and the one at UCLA
survival time was censored at the time of UNOS 2 trans-
plant. However, 41% of the UCLA sample (and 49% of
those actually listed for transplant) received a UNOS 2
transplant versus 29% at HUP and 23% at CPMC. When
survival data on a patient are censored, actuarial survival
methods assume that the patient’s probability of survival
beyond the time of censoring would have been the same as
that for patients for whom survival data can continue to be
collected. While there is no a priori reason to believe that
this was not true for the UCLA series, the large proportion
of censored outcomes makes the analysis dependent on the
survival experience of a relatively small proportion of pa-
tients.
Our study also differed from the study of Stevenson et al.
(19) in that we treated UNOS status 1 and LVAD insertion
as equivalent to death, whereas UNOS 1 transplant was
censored in the UCLA study (LVADs were not used in the
UCLA study). This difference is reflected in lower event-
free survival rates for the entire HUP and CPMC cohorts
than for the UCLA cohort. However, censoring for UNOS
status 1 transplant and LVAD insertion is very misleading.
Patients who require intravenous inotropes or an LVAD to
survive cannot be expected to have the same likelihood of
survival without a transplant as patients who are less ill and
remain on the outpatient waiting list. Although treating
UNOS 1 transplant or LVAD as equivalent to death is also
problematic—patients receiving these interventions have
not died—the expected survival experience of these patients
is much closer to that of patients who have died than it is to
patients who remain on the UNOS status 2 waiting list.
It is also important to consider whether the clinical
approach to care taken by Stevenson et al. (26–29) was
responsible for the improved outcomes for six-month sur-
vivors. These investigators have suggested that “tailored
therapy,” a program of high-dose diuretics and vasodilators
titrated to hemodynamic goals, results in improved out-
comes when applied to patients with advanced heart failure
referred for cardiac transplant evaluation (26–28). However,
it is likely that many of these patients were receiving
suboptimal therapy when initially referred for evaluation,
and it is not clear whether any benefit derived from tailored
therapy would not have followed conventional optimization
of medical therapy with digoxin, a diuretic and target doses
of an ACE inhibitor. This remains only speculative as no
randomized clinical trial has ever compared tailored therapy
to contemporary standard heart failure therapy.
No patient received an urgent (UNOS status 1) trans-
plant, and nearly all of the deaths were sudden for patients
who survived the initial six months after listing in the
UCLA series. In our two samples, the majority of events
were UNOS status 1 transplants in patients who experi-
enced hemodynamic deterioration requiring inotropic
bridging to transplant. This is consistent with the advanced
state of heart failure for listed patients in our samples and is
also consistent with the experience reported by Kao et al.
(26).
Both Stevenson et al. (29) and Levine et al. (30) have
reported the frequent occurrence of listed patients who
experience substantial objective and subjective clinical im-
provement allowing successful removal from the waiting list.
However, clinical improvement warranting removal from
the transplant waiting list was unusual in both of our
samples. When objective criteria emphasizing peak V˙O2
obtained after optimizing medical therapy are used to select
ambulatory patients for placement on a transplant waiting
list, substantial clinical improvement should be uncommon.
Patients with a recent onset of a nonischemic cardiomyop-
athy constitute an important exception. At both centers, we
frequently deferred transplant listing for a few months in
these patients to allow for spontaneous improvement. Nev-
ertheless, we believe that all listed patients should undergo
serial reevaluations at 6-month intervals (or sooner if there
appears to be substantial improvement) to identify patients
who may be removed from the waiting list.
Study limitations. The use of UNOS status 1 transplant as
an end point equivalent to death represents a limitation of
the study. However, the need for urgent transplantation or
implantation of an LVAD does signify critical clinical
deterioration and disease progression. Whereas combining
UNOS 1 transplant and death overstates the “true” mortal-
ity rate that would exist if heart transplant were not
available, using death alone as the outcome would under-
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state the “true” mortality. This study is also limited in that
the data collected reflects the practice of two large transplant
centers and not the entire country.
Clinical implications and conclusions. From 1988 to
1995 median waiting time for a donor heart increased from
122 days to 213 days (2). In a multivariable analysis of
factors predictive of waiting time in the UNOS registry
from April 1994 through April 1996, patients who spent all
of their waiting time as outpatients had a 7.3-fold longer
wait (J.M. Chen, personal communication, 1997). Patients
experiencing these prolonged waiting times remain at sub-
stantially increased risk of dying and should continue to
receive priority for a donor organ.
We have shown that high-risk patients can be identified
when objective criteria emphasizing reduced peak V˙O2 are
used to select transplant candidates. For such patients,
mortality remains high, even among those who survive an
initial six months after placement on the waiting list.
Improvement of a sufficient degree to allow removal from
the transplant list is infrequent in these circumstances.
Therefore, time accrued on the outpatient waiting list
remains an appropriate criterion for donor allocation.
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